Androgen News and Research RSS Feed - Androgen News and Research

Childhood obesity linked to early puberty

Childhood obesity linked to early puberty

A new link has been identified between obesity in childhood and the lowering of the age of puberty. [More]
Research roundup: ACA lawsuit primer; ACA strategies in 4 states; competitive plans for those eligible for Medicare and Medicaid

Research roundup: ACA lawsuit primer; ACA strategies in 4 states; competitive plans for those eligible for Medicare and Medicaid

In 2012, the U.S. Supreme Court upheld the constitutionality of the ACA, but that did not end attacks against the law. Since the decision in National Federation of Independent Business v. Sebelius, objecting parties have filed more than 100 cases in federal courts nationwide. [More]
Letrozole drug results in higher birth rates in women with PCOS

Letrozole drug results in higher birth rates in women with PCOS

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine researchers. [More]
Men with prostate cancer achieve stronger muscles and remain active through playing football

Men with prostate cancer achieve stronger muscles and remain active through playing football

Men with prostate cancer aged 43‒74 achieve bigger and stronger muscles, improve functional capacity, gain positive social experiences and the desire to remain active through playing football for 12 weeks. [More]
Androgen sensitivity may contribute to hypertrichosis in girls

Androgen sensitivity may contribute to hypertrichosis in girls

Prepubertal girls with hypertrichosis are likely to have genetic variants of the androgen receptor known to be particularly sensitive to androgen, say researchers. [More]
Study examines effect of phthalate exposure in humans’ sperm epigenetics

Study examines effect of phthalate exposure in humans’ sperm epigenetics

A new three-year, $440,000 study led by environmental health scientist Richard Pilsner at the University of Massachusetts Amherst is now underway to investigate whether phthalate levels in expectant fathers have an effect on the couples' reproductive success, via epigenetic modifications of sperm DNA. [More]
Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment. [More]
New targets could increase effectiveness and reduce side effects linked with breast cancer treatments

New targets could increase effectiveness and reduce side effects linked with breast cancer treatments

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable side effects associated with current treatments. [More]
Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

Endocrine Society announces winners of Early Investigators Awards and FLARE Internship Awards

The Endocrine Society is pleased to announce the recipients of the 2014 Early Investigators Awards and the Future Leaders Advancing Research in Endocrinology Internship Awards. [More]
New targets found for potential intervention in breast cancer

New targets found for potential intervention in breast cancer

Scientists from the Florida campus of The Scripps Research Institute have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable side effects associated with current treatments. [More]
Enzalutamide drug proves effective in stemming progression of prostate cancer

Enzalutamide drug proves effective in stemming progression of prostate cancer

A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University. [More]
New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group. [More]
Scientists define genetic cause for two types of birth defects in newborn boys

Scientists define genetic cause for two types of birth defects in newborn boys

Baylor College of Medicine scientists defined a previously unrecognized genetic cause for two types of birth defects found in newborn boys, described in a report published today in the journal Nature Medicine. [More]
FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [More]
New simple screening questionnaire designed to identify testosterone-deficient men

New simple screening questionnaire designed to identify testosterone-deficient men

Men whose testosterone falls below normal levels are more likely to have erectile dysfunction and to be overweight and have heart disease and type 2 diabetes. [More]
New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy. [More]
NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. [More]
Radiation plus hormones offers best outcomes for localised prostate cancer

Radiation plus hormones offers best outcomes for localised prostate cancer

The combination of radiotherapy and androgen deprivation therapy is more effective than radiotherapy alone for preventing disease recurrence in men with localised prostate cancer, according to research findings presented at the European Society for Radiotherapy and Oncology 33rd annual congress in Vienna, Austria. [More]
6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

6 months of hormonal treatment in addition to radiotherapy improves outcome for prostate cancer

Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research. [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]